EV 25
Alternative Names: EV-25Latest Information Update: 23 Oct 2025
At a glance
- Originator ERADIVIR
- Class Antivirals; Bispecific antibodies; Haptens; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Influenza virus infections
Most Recent Events
- 15 Oct 2025 Immunogenicity, pharmacokinetics and adverse events data from phase I/II trial in Influenza virus infections released by Eradivir
- 15 Oct 2025 Eradivir plans phase IIb trial in Influenza virus infections in the US and Europe in 2026-2027 (Intranasal, Powder)
- 28 Jul 2025 ERADIVIR temporarily halts phase I trial in Influenza virus infections (In volunteers) in Belgium (Intranasal) (EudraCT2025-521783-35-00)